SEC Filings

Form S-3
ARALEZ PHARMACEUTICALS INC. filed this Form S-3 on 11/09/2017
Document Outline
Entire Document (806 KB)
Subdocument 1 - S-3 - S-3
Page 1 - As filed with the Securities and Exchange Commission on November 9, 2017
Page 2 - The information in this prospectus is not complete and may be changed. We may not sell these securit
Page 3 - TABLE OF CONTENTS
Page 4 - ABOUT THIS PROSPECTUS
Page 5 - ABOUT ARALEZ
Page 6 - Business Strategy
Page 7 - Marketed Products United States
Page 8 - pharmacokinetics
Page 9 - Proferrin
Page 10 - Out-Licensed Products
Page 11 - Product Pipeline Updates
Page 12 - RISK FACTORS
Page 13 - SECURITIES WE MAY OFFER
Page 14 - DESCRIPTION OF SHARE CAPITAL
Page 15 - Anti-Takeover Provisions
Page 16 - Indemnification of Officers and Directors
Page 17 - Limitation on Director Liability
Page 18 - DESCRIPTION OF WARRANTS
Page 19 - DESCRIPTION OF DEBT SECURITIES
Page 20 - Form of Debt Securities
Page 21 - Modification of the Indenture or Other Indentures
Page 22 - Concerning the Trustee
Page 23 - PLAN OF DISTRIBUTION
Page 24 - Delayed Delivery Contracts
Page 25 - General Information
Page 26 - WHERE YOU CAN FIND MORE INFORMATION
Page 27 - N/A
Page 28 - Common Shares
Page 29 - PART II
Page 30 - Item 16. Exhibits.
Page 31 - bona fide
Page 32 - N/A
Page 33 - INDEX TO EXHIBITS
Page 34 - SIGNATURES
Page 35 - N/A
Page 36 - SIGNATURE OF AUTHORIZED REPRESENTATIVE IN THE UNITED STATES
Page 37 - Exhibit 12.1
Subdocument 2 - EX-4.1 - EX-4.1
Page 1 - Exhibit 4.1
Page 2 - CROSS REFERENCE TABLE
Page 3 - N/A
Page 4 - N/A
Page 5 - N/A
Page 6 - N/A
Page 7 - N/A
Page 8 - N/A
Page 9 - N/A
Page 10 - provided
Page 11 - N/A
Page 12 - N/A
Page 13 - N/A
Page 14 - N/A
Page 15 - N/A
Page 16 - N/A
Page 17 - N/A
Page 18 - N/A
Page 19 - provided
Page 20 - N/A
Page 21 - N/A
Page 22 - N/A
Page 23 - N/A
Page 24 - i.e.
Page 25 - N/A
Page 26 - N/A
Page 27 - EXHIBIT A
Page 28 - (Form of Reverse of Security)
Page 29 - Remedies
Page 30 - ASSIGNMENT FORM
Subdocument 3 - EX-5.1 - EX-5.1
Page 1 - Exhibit 5.1
Page 2 - N/A
Page 3 - N/A
Page 4 - Very truly yours, /s/ Willkie Farr Gallagher LLP 4
Subdocument 4 - EX-5.2 - EX-5.2
Page 1 - Exhibit 5.2
Page 2 - Indentures
Page 3 - 3. The warrants will, when authorized for issuance by the Board, be duly authorized by all necessary
Subdocument 5 - EX-12.1 - EX-12.1
Page 1 - Exhibit 12.1
Page 2 - N/A
Subdocument 6 - EX-23.1 - EX-23.1
Page 1 - Exhibit 23.1
Subdocument 7 - EX-23.4 - EX-23.4
Page 1 - Exhibit 23.4
Subdocument 8 - EX-23.5 - EX-23.5
Page 1 - Exhibit 23.5
Subdocument 9 - EX-23.6 - EX-23.6
Page 1 - Exhibit 23.6

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.